MicuRx Pharmaceuticals Announces Promising Results from MRX-5 Study for Treating Mycobacterium abscessus Infections

Posted on by

FOSTER CITY, Calif., Oct. 8, 2024 /PRNewswire/ — MicuRx Pharmaceuticals is excited to announce the publication of groundbreaking research on MRX-5, a novel oral oxaborole prodrug, demonstrating significant potential in the treatment of pulmonary infections caused by Mycobacterium…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.